Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $34.83 Average PT from Brokerages

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $30.6667.

A number of equities analysts have issued reports on GLUE shares. JPMorgan Chase & Co. increased their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. Guggenheim upped their target price on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Wedbush decreased their target price on Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, COO Jennifer Champoux sold 2,176 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total transaction of $41,344.00. Following the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,185,049. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $23.11, for a total transaction of $231,100.00. Following the sale, the director directly owned 10,000 shares of the company’s stock, valued at $231,100. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 81,778 shares of company stock valued at $1,768,581. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several large investors have recently bought and sold shares of GLUE. Price T Rowe Associates Inc. MD lifted its position in shares of Monte Rosa Therapeutics by 10.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after acquiring an additional 481,844 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after purchasing an additional 257,547 shares in the last quarter. State Street Corp raised its stake in Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. AQR Capital Management LLC raised its stake in Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after purchasing an additional 1,054,406 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 4.6% in the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock valued at $18,896,000 after purchasing an additional 53,278 shares in the last quarter. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Stock Performance

Shares of Monte Rosa Therapeutics stock opened at $15.38 on Thursday. The firm has a 50-day simple moving average of $20.81 and a two-hundred day simple moving average of $19.54. The company has a market cap of $1.30 billion, a P/E ratio of -10.39 and a beta of 1.59. Monte Rosa Therapeutics has a fifty-two week low of $4.12 and a fifty-two week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Equities research analysts forecast that Monte Rosa Therapeutics will post -1.23 EPS for the current year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.